Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11876
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBach, Leon Aen
dc.contributor.authorCooper, Mark Een
dc.contributor.authorO'Brien, R Cen
dc.contributor.authorJerums, Georgeen
dc.date.accessioned2015-05-16T01:30:25Z
dc.date.available2015-05-16T01:30:25Z
dc.date.issued1990-01-01en
dc.identifier.citationJournal of the American Geriatrics Society; 38(1): 10-4en
dc.identifier.govdoc2404052en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11876en
dc.description.abstractEpidemiological evidence suggests that elevated serum cholesterol, especially the low density lipoprotein (LDL) fraction, the total/high density lipoprotein (HDL)-cholesterol ratio, and the LDL/HDL-cholesterol ratio, remains a risk factor for atheromatous disease up to the age of 79 years. We studied the efficacy and tolerability of simvastatin, an HMG CoA reductase inhibitor, in 20 patients aged 65 to 75 years with clinical evidence of atheromatous disease. After four weeks of treatment, there was a 29% fall in LDL-cholesterol levels (P less than .01 vs placebo) with low dose simvastatin and a 38% fall with high dose simvastatin (P less than .001 vs placebo). Similar falls were seen in total cholesterol levels and the LDL/HDL-cholesterol and total/HDL-cholesterol ratios. Apoprotein B levels decreased by approximately 20% with both doses (P less than .05 vs placebo). In an open extension of the study, the decreases in lipid parameters were sustained for a further 48 weeks of treatment with doses of simvastatin ranging from 10 to 40 mg. Two patients required the addition of cholestyramine. Although a small study like this cannot establish safety and tolerance, side effects were minor and did not require stopping therapy in any patient. Simvastatin is an effective cholesterol lowering agent in older patients.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAnticholesteremic Agents.administration & dosage.adverse effects.therapeutic useen
dc.subject.otherArteriosclerosis.blood.drug therapyen
dc.subject.otherCataract.chemically induced.drug therapyen
dc.subject.otherCholesterol, HDL.blooden
dc.subject.otherCholesterol, LDL.blooden
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherFemaleen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherHypercholesterolemia.blood.drug therapyen
dc.subject.otherLovastatin.administration & dosage.adverse effects.analogs & derivatives.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherRandomized Controlled Trials as Topicen
dc.subject.otherSimvastatinen
dc.titleThe use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of the American Geriatrics Societyen
dc.identifier.affiliationEndocrine Unit, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages10-4en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2404052en
dc.type.austinJournal Articleen
local.name.researcherJerums, George
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Nov 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.